Jia Jie “Jennifer” Tang is a life sciences patent attorney who brings extensive legal experience and technical expertise in biotechnology and medical devices to advise clients on sophisticated intellectual property strategy. Her practice focuses on developing, managing, and executing global patent portfolios that support product development, investment, and long-term business objectives.
Jennifer counsels clients on portfolio architecture, including technology mapping, claim-scope optimization, continuation and divisional strategies, lifecycle management, and coordination of U.S. and international filings. She routinely conducts and oversees patent landscape analyses and freedom-to-operate assessments to identify risk, inform R&D direction, and guide transactional and commercialization decisions.
Her patent prosecution experience spans a wide range of technologies, including immunotherapies, antibodies, nucleic acid therapeutics, gene-editing platforms, and medical devices. Jennifer works closely with scientists, engineers, and in-house legal teams to translate complex innovations into strategically aligned patent protection.
Prior to joining MBHB, Jennifer was an Associate at Morgan, Lewis & Bockius LLP, where she drafted and prosecuted patent applications and provided strategic IP counseling for life sciences and medical device clients across all stages of development.
*Not yet admitted in Illinois. Currently licensed in Massachusetts.
J. J. Tang, et al. Natural Killer (NK) Cell Expression of CD2 as a Predictor of Serial Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC). Antibodies (Basel). 2020 Oct 16;9(4):54.
Co-author. An improved method to quantify human NK cell-mediated antibody-dependent cell-mediated cytotoxicity (ADCC) per IgG FcR-positive NK cell without purification of NK cells. D J Immunol Methods. 2017 Nov 4. pii: S0022-1759(17)30429-5.
Co-author. Antibody-Dependent Cell-mediated Cytotoxicity (ADCC) in Familial Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Fatigue. 2020;8(4):226-244.
Co-author. Inclusion of family members without ME/CFS in research studies promotes discovery of biomarkers specific for ME/CFS. Work. 2020;66(2):327-337.
